Trial Profile
Randomized Blinded Phase III Assessment of Second or Third-Line Chemotherapy With Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced Non-Small Cell Lung Cancer and With at Least One Measurable Lung Lesion
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Jul 2023
Price :
$35
*
At a glance
- Drugs Plinabulin (Primary) ; Docetaxel
- Indications Neutropenia; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms DUBLIN-3
- Sponsors BeyondSpring Pharmaceuticals
- 06 Jun 2023 Results of post-hoc analysis assessing safety, tolerability, and QoL in NSCLC patients from these trials, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2023 Results assessing the correlation of Plins anticancer effects with NLR, PLR, LMR immune suppressive biomarkers to select non-small cell lung cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology